Spondyloarthritis & psoriatic arthritis
The metabolic score for insulin resistance predicts the risk of cardiovascular disease in patients with psoriatic arthritis: results from the 10-year prospective CARdiovascular in ReuMAtology (CARMA) cohort
Authors' conclusion
In PsA patients under close observation in rheumatology units included in the prospective CARMA project, METS-IR serves as a reliable prognostic predictor of CV.
Study context
- Population
- PsA patients without history of cardiovascular (CV) events, CKD, diabetes mellitus or statin use, Spanish CARMA project, rheumatology outpatient clinics at tertiary centres
- Participants
- 500 patients4,788 patient-years
- Exposure
- Metabolic score for insulin resistance (METS-IR) categories <2.25 vs 2.25-2.48 vs >2.48
- Outcome
- CV events
- Follow-up
- 10 years
Methodological details10-year follow-up, multicentre (tertiary centres)
- 10-year follow-up
- Multicentre (tertiary centres)
Main finding
As reported in the abstract
METS-IR score at baseline, patients with vs without CV events
With CV events
2.37
± 0.24
Without CV events
2.26
± 0.19
P = 0.01
Observational data: associations, not effects.
Further findings
| Outcome | P value |
|---|---|
| Distribution across METS-IR categories, patients with vs without CV events | P = 0.008 |
- Distribution across METS-IR categories, patients with vs without CV events: CV events more common in METS-IR 2.25-2.48 and >2.48 categories
CV event incidence
- Individuals with at least one CV event
- 27
- Annualised incidence rate, events per 1000 patient-years
- 5.6 (95% CI 3.7 to 8.2)
Original publication
The metabolic score for insulin resistance predicts the risk of cardiovascular disease in patients with psoriatic arthritis: results from the 10-year prospective CARMA cohort. RMD Open. Published 7 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →